Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 1/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.39 |
| ▸ | ABAT | P80404 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 6/20 | 0.35 |
| ▸ | NOS2 | P35228 | 6/20 | 0.35 |
| ▸ | NOS3 | P29474 | 4/20 | 0.35 |
| ▸ | LPL | P06858 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3780654 | 0.83 | LPL (0.48) | F11NOS1NOS2NOS3LPL | |
| SCHEMBL3785854 | 0.83 | ENPP2 (0.44) | F11ENPP2NOS1NOS3LPL | |
| SCHEMBL25381438 | 0.82 | GAA (0.33) | F11LPLLIPGGAAALDH1A1 | |
| SCHEMBL24803737 | 0.79 | F11 (0.47) | F11LOXL2ABATENPP2HRH3 | |
| SCHEMBL2560402 | 0.79 | GABRA1 (0.46) | ALDH1A1CYP3A4NFKB1 | |
| SCHEMBL3786518 | 0.77 | SKP2 (0.56) | LPLLIPGALDH1A1SMN1; SMN2CYP3A4 | |
| SCHEMBL27207991 | 0.77 | SLC6A2 (0.44) | LPLLIPGGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL16635109 | 0.75 | F11 (0.47) | F11LOXL2ABATENPP2HRH3 | |
| SCHEMBL9939178 | 0.73 | F11 (0.45) | F11LOXL2ABATENPP2HRH3 | |
| SCHEMBL14287217 | 0.73 | CASP1 (0.48) | ENPP2GAAALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168651-B2 | Protein kinase modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | PIM1, PIM2, PIM3 | F11 2329/4885LOXL2 3824/4885ABAT 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.